Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,188.55 +7.81 (+0.15%) Dow
38,955.80 +103.53 (+0.27%) Nasdaq
16,339.39 -9.86 (-0.06%) Bitcoin USD
63,249.18 -662.64 (-1.04%) CMC Crypto 200
1,313.13 -52.00 (-3.81%)
Phathom Pharmaceuticals, Inc. (PHAT)
| Previous close | 10.84 |
| Open | 10.84 |
| Bid | 10.40 x 200 |
| Ask | 10.59 x 100 |
| Day's range | 10.46 - 11.02 |
| 52-week range | 6.07 - 17.02 |
| Volume | |
| Avg. volume | 884,409 |
| Market cap | 612.162M |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, May 9, 2024, to report its first quarter 2024 financial results and provide an update on business progress. A live webcast and a
- GlobeNewswire
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 9:30 a.m. ET. Company management will also participate in one-on-one meetings during the conference, wh
- GlobeNewswire
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB) A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for g
